


AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.



1. (Currently Amended) A compound represented by the formula (I)




(I)

wherein

A is a group represented by the following formula ~~(A1)~~, (A2) or ~~(A3)~~

~~(A1)~~

(A2)

~~(A3)~~

B is a ~~1H-tetrazol-5-yl group~~ or a 2,4-dioxothiazolidin-5-yl group,

X is methylene, an oxygen atom or a sulfur atom,

Y is a single bond or a C6-10 arylene group,

R^{1A} is a hydrogen atom or a C1-6 alkyl group,

R^{2A} and R^{3A} are the same or different and each is a hydrogen atom, a carboxyl group or a C1-6 alkyl group,

R^{4A}, R^{5A} and R^{6A} are the same or different and each is a hydrogen atom or a C1-6 alkyl group, and

R^{7A} is a C1-10 alkyl carbonyl group,

~~provided that when A is (A2), then B should be a 2,4-dioxothiazolidin-5-yl group,~~
or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof.

2. (Canceled)

3. (Currently Amended) The compound of claim 1, wherein Y is a C6-10 arylene group, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof.

4. (Currently Amended) The compound of claim 1, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof.

5.-9. (Canceled)

10. (Currently Amended) ~~A~~ The compound selected from the group consisting of

~~3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-pentanoylamino]benzoic acid,~~

~~3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-butanoylamino]benzoic acid,~~

~~3-[N-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-N-heptanoylamino]benzoic acid,~~

~~2-oxo-3-propyl-1-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3,4-trihydroquinoline-7-carboxylic acid and~~

~~5-[4-[(2-ethyl-5,7-dimethylimidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1,3-thiazolidine-2,4-dione,~~
or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof.

11. (Canceled)

12. (Currently Amended) A ~~medicament~~ pharmaceutical composition comprising (a) the compound of claim ~~5~~ 1, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, and (b) a carrier therefor.

13. (Canceled)

14. (Currently Amended) A pharmaceutical composition ~~for the prophylaxis or treatment of diabetic complication, which comprises~~ comprising (a) the compound of claim ~~5~~ 3, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, and (b) a carrier therefor.

15. (Currently Amended) A pharmaceutical composition ~~for the prophylaxis or treatment of diabetic complication, which comprises~~ comprising (a) the

compound of claim ~~5~~ 4, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, and (b) a carrier therefor.

16.-19. (Canceled)

20. (Currently Amended) A method of treating diabetic nephropathy by inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim ~~5~~ 1, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, to the warm-blooded animal, whereupon diabetic nephropathy is treated.

21. (Currently Amended) A method of ~~preventing or~~ treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim ~~5~~ 1, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, to the warm-blooded animal.

22.-27. (Canceled)

28. (Currently Amended) The compound of claim 3, wherein Y is a phenylene group, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof.

29. (Canceled)

30. (Canceled)

31. (Currently Amended) A pharmaceutical composition ~~for the prophylaxis or treatment of diabetic complication, which comprises~~ comprising (a) the compound of claim ~~7~~ 28, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, and (b) a carrier therefor.

32. (Currently Amended) A pharmaceutical composition ~~for the prophylaxis or treatment of diabetic nephropathy, which comprises~~ comprising (a) the compound of claim ~~7~~ 10, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, and (b) a carrier therefor.

33. (Currently Amended) A method of treating diabetic nephropathy by inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim ~~7~~ 3, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, to the warm-blooded animal, whereupon diabetic nephropathy is treated.

34. (Currently Amended) A method of ~~preventing or~~ treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim ~~7~~ 3, or a pharmacologically acceptable salt thereof or ~~an~~ a carboxylate ester thereof, to the warm-blooded animal.

35. (Canceled)

36. (New) A method of treating diabetic nephropathy by inhibiting AGEs formation in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 10, or a pharmacologically acceptable salt thereof or a carboxylate ester thereof, to the warm-blooded animal, whereupon diabetic nephropathy is treated.

37. (New) A method of treating diabetic complication in a warm-blooded animal, which comprises administering a pharmacological effective amount of the compound of claim 10, or a pharmacologically acceptable salt thereof or a carboxylate ester thereof, to the warm-blooded animal.